西格列汀联合二甲双胍对新诊断2型糖尿病患者血糖及胰岛β细胞功能的影响

Effect of sitagliptin plus metformin on lowering blood glucose and improving pancreatic β cell in newly diagnosed type 2 diabetes mellitus

目的探讨西格列汀联合二甲双胍对新诊断2型糖尿病(T2DM)患者血糖及胰岛β细胞功能的影响。方法将84例T2DM患者随机分为两组,各42例。两组患者均给予二甲双胍常规治疗,观察组在此基础上加用磷酸西格列汀治疗。测定两组治疗前后血糖[空腹血糖(FBG)、餐后2 h血糖(2h PPG)]及胰岛β细胞功能[空腹胰岛素(FIns)、空腹C肽及餐后2 h C肽]水平,并观察两组不良反应发生情况。结果两组治疗前血糖及胰岛β细胞功能指标比较,差异均无统计学意义(P>0.05);观察组治疗后血糖水平低于对照组,Fins、空腹C肽及餐后2 h C肽水平均高于对照组,差异有统计学意义(P<0.05或P<0.01);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论西格列汀联合二甲双胍可有效降低新诊断T2DM患者的血糖水平,利于改善胰岛β细胞功能,且安全性较高。

Objective To investigate the impact of sitagliptin plus with metformin on blood glucose and pancreatic β cell in newly diagnosed type 2 diabetes mellitus (T2DM).Methods Eighty-four cases of newly diagnosed T2DM were randomly divided into control group and observation group by number table,with 42 cases in each group. All of the patients received oral metformin ,and observation group did sitagliptin phosphate in addition.The blood glucose [fasting blood glucose(FBG),2 h postprandial blood glucose] and pancreatic β cell function [fasting insulin(FIns), fasting C-peptide,2 h postprandial C- peptide] in two groups were assessed before and after treatment.The adverse reactions were compared in the two groups.Results Before treatment, there was no statistical difference in the blood glucose concentration and pancreatic β cell function between the two groups( P >0.05);After treatment,observation group got a lower level of blood glucose than that of control group, while observation group obtained higher concentrations in Fins, fasting C-peptide,and 2 h postprandial C- peptide than those of control group ( P <0.05 or P <0.01);No statistical difference in the incidence of adverse reactions was observed between the two groups( P >0.05).Conclusion Sitagliptin concomitant with metformin achieved better outcomes than single sitagliptin in lowering blood glucose concentration and improving pancreatic β cell function in the therapy for newly diagnosed T2DM.